Number of the records: 1  

Glycomimetic inhibitors of tandem-repeat galectins: Simple and efficient

  1. 1.
    SYSNO ASEP0585278
    Document TypeJ - Journal Article
    R&D Document TypeJournal Article
    Subsidiary JČlánek ve WOS
    TitleGlycomimetic inhibitors of tandem-repeat galectins: Simple and efficient
    Author(s) Vrbata, David (MBU-M) ORCID
    Červený, Jakub (MBU-M) ORCID, RID
    Kulik, Natalia (MBU-M) ORCID
    Hovorková, Michaela (MBU-M)
    Balogová, Soňa (MBU-M)
    Vlachová, Miluše (MBU-M) ORCID
    Pelantová, Helena (MBU-M) ORCID, RID
    Křen, Vladimír (MBU-M) RID, ORCID
    Bojarová, Pavla (MBU-M) ORCID
    Article number107231
    Source TitleBioorganic Chemistry. - : Elsevier - ISSN 0045-2068
    Roč. 145, April 24 (2024)
    Number of pages13 s.
    Languageeng - English
    CountryNL - Netherlands
    Keywordscarbohydrate-recognition ; domain ; lectin ; oligosaccharide ; optimization ; expression ; crystal ; docking ; Glycomimetic ; Molecular modeling ; Tandem-repeat galectin ; Structure-affinity relationship ; Thiodigalactoside
    OECD categoryBiochemistry and molecular biology
    R&D ProjectsGA22-00262S GA ČR - Czech Science Foundation (CSF)
    LUC23148 GA MŠMT - Ministry of Education, Youth and Sports (MEYS)
    Research Infrastructuree-INFRA CZ II - 90254 - CESNET, zájmové sdružení právnických osob
    Method of publishingLimited access
    Institutional supportMBU-M - RVO:61388971
    UT WOS001197668500001
    EID SCOPUS85186065776
    DOI10.1016/j.bioorg.2024.107231
    AnnotationThe binding of human galectins by glycomimetic inhibitors is a promising therapeutic approach. The structurally distinct group of tandem-repeat galectins has scarcely been studied so far, and there is hardly any knowledge on their ligand specificity or their inhibitory potential, particularly concerning non-natural carbohydrates. Here, we present the synthesis of a library of seven 3-O-disubstituted thiodigalactoside-derived glycomimetics and their affinity to two tandem-repeat galectins, Gal-8 and Gal-9. The straightforward synthesis of these glycomimetics involved dibutyltin oxide-catalyzed 3,3-O-disubstitution of commercially available unprotected thiodigalactoside, and conjugation of various aryl substituents by copper-catalyzed Huisgen azide-alkyne cycloaddition (CuAAC). The inhibitory potential of the prepared glycomimetics for Gal-8 and Gal-9 was assessed, and compared with the established galectins Gal-1 and Gal-3. The introduction of C-3 substituents resulted in an over 40-fold increase in affinity compared with unmodified TDG. The structure-affinity relations within the studied series were discussed using molecular modeling. Furthermore, the prepared glycomimetics were shown to scavenge Gal-8 and Gal-9 from the surface of cancer cells. This pioneering study on the synthetic inhibitors especially of Gal-9 identified lead compounds that may be used in further biomedical research.
    WorkplaceInstitute of Microbiology
    ContactEliška Spurná, eliska.spurna@biomed.cas.cz, Tel.: 241 062 231
    Year of Publishing2025
    Electronic addresshttps://www.sciencedirect.com/science/article/pii/S0045206824001366?via%3Dihub
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.